The real question is the exit pathway, not timing. Based on Baker Bros.' history, a voluntary open-market sale is unlikely near-term. The more probable eventual outcome would be:
Acquisition by a large pharma (Roche, Novartis, AbbVie, etc. are all active in retinal disease) if the Phase 3 data is positive — this is the classic Baker Bros. "exit". my emphasis
Long-term hold if Kodiak becomes a commercial-stage company on its own
Bottom line: The chances they sell KOD in the near term are low. They're in accumulation mode, the data catalysts are still ahead, and this fits their classic pattern of riding a position through its most critical inflection point. The more likely scenario is they hold through the 2026 Phase 3 readouts, and if successful, either hold even longer or get taken out via M&A.
This was before todays results
I go with the " get taken out via M&A "
Kiwi
Recent KOD News
- Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference • PR Newswire (US) • 05/28/2026 10:09:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 12:00:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:15:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:00:20 PM
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results • PR Newswire (US) • 05/07/2026 08:00:00 PM
- Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences • PR Newswire (US) • 05/01/2026 04:23:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:18:39 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/22/2026 08:14:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 09:00:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 12:26:22 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:23:25 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/02/2026 08:10:31 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/31/2026 09:21:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:02:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 08:54:55 PM
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results • PR Newswire (US) • 03/31/2026 08:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 10:08:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 01:56:48 AM
- Kodiak Sciences shares jump on encouraging Phase 3 trial results • IH Market News • 03/26/2026 02:26:50 PM
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham • PR Newswire (US) • 03/26/2026 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/19/2026 09:07:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:35:12 PM
- Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 • PR Newswire (US) • 02/04/2026 12:00:00 PM
